The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Drug Resistance Updates Année : 2016

The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target

Résumé

Proliferating cells reduce their oxidative metabolism and rely more on glycolysis, even in the presence of O 2 (Warburg effect). This shift in metabolism reduces citrate biosynthesis and diminishes intracellular acidity, both of which promote glycolysis sustaining tumor growth. Because citrate is the donor of acetyl-CoA, its reduced production favors a deacetylation state of proteins favoring resistance to apoptosis and epigenetic changes, both processes contributing to tumor aggressiveness. Citrate levels could be monitored as an indicator of cancer aggressiveness (as already shown in human prostate cancer) and/or could serve as a biomarker for response to therapy. Strategies aiming to increase cytosolic citrate should be developed and tested in humans, knowing that experimental studies have shown that administration of citrate and/or inhibition of ACLY arrest tumor growth, inhibit the expression of the key anti-apoptotic factor Mcl-1, reverse cell dedifferentiation and increase sensibility to cisplatin.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée

Dates et versions

inserm-01427151 , version 1 (05-01-2017)

Identifiants

Citer

Icard Philippe, Lincet Hubert. The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target. Drug Resistance Updates, 2016, 29, pp.47 - 53. ⟨10.1016/j.drup.2016.09.003⟩. ⟨inserm-01427151⟩
84 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More